Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 183Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 125Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 61abiraterone 58cabozantinib 56Carboplatin 56Leuprolide 53enfortumab vedotin 50Radiation 48Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
carotuximab × Genitourinary × 1 year × Clear all
NCT05534646 2026-02-02

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Cedars-Sinai Medical Center

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡